Release Date: 24/11/16 10:52 Summary: CEO Presentation to Shareholders Price Sensitive: Yes Download Document 2.68MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%